title: Sustained ocular hypertension following intravitreal injections of 0.5 mg/0.05 ml ranibizumab.
abstract: To report three cases with sustained ocular hypertension following intravitreal injections of 0.5 mg/0.05 ml ranibizumab and to underline the importance of monitoring intraocular pressure (IOP) following intravitreal injections of ranibizumab (Lucentis). Three patients were found to have high IOP after intravitreal injections of 0.5 mg/0.05 ml ranibizumab. IOP was elevated after the second ranibizumab injection in patients 1 and 2, and after the third injection in patient 3. The increase in IOP was sustained, requiring treatment with anti-glaucoma eye drops in all patients, the addition of systemic carbonic anhydrase inhibitor in one patient, and the application of selective laser trabeculoplasty (SLT) in another patient. None of the patients had a previous history of glaucoma or ocular hypertension. Sustained ocular hypertension may occur after intravitreal injections of 0.5 mg/0.05 ml ranibizumab. Although the precise mechanism of the pressure rise is unknown, three eyes in our series were controlled with topical or oral medication and one with SLT. The necessity of IOP monitoring is strongly emphasized after intravitreal injections of 0.5 mg/0.05 ml ranibizumab.
authors: Moorfields Eye Hospital, 25A Bavaria Road, Islington, London, UK. eleniloukianou@yahoo.com
authors: Eleni
authors: E
authors: Loukianou
authors: Dimitrios
authors: D
authors: Brouzas
authors: Michael
authors: M
authors: Apostolopoulos
references: N Engl J Med. 2006 Oct 5;355(14):1419-31
references: 17021318
references: Mol Vis. 2006 Feb 27;12:125-41
references: 16541013
references: Eye (Lond). 2009 Jan;23(1):181-5
references: 17693999
references: N Engl J Med. 2006 Oct 5;355(14):1432-44
references: 17021319
references: J Glaucoma. 2006 Apr;15(2):117-9
references: 16633224
references: Ophthalmic Res. 2007;39(6):330-7
references: 18046086